Quick answer: Adult stem cell therapy has been legal in Costa Rica since 2016, authorised by presidential decree 39,986-S under a defined regulatory framework. The Ministry of Health licenses clinics and oversees the sector alongside the National Council for Science and Technology and the National Advisory Committee on Bioethics. The framework distinguishes minimally manipulated from more than minimally manipulated cells, with different authorisation routes for each.
This is a regulated permission, not an absence of regulation — a distinction that matters both for patients evaluating clinics and for anyone assuming Costa Rica operates as an unregulated frontier. It does not.
What the framework actually requires
The decree separates therapies by degree of manipulation. For adult stem cell therapies intended for exclusive autologous use — using the patient own cells — with minimal manipulation, clinicians must submit a request to the health authority including scientifically reasoned justification that the procedure has a reasonable chance of success, supported by preclinical or clinical evidence of efficacy and safety.
Facilities must hold a valid health facility licence (habilitación) under Decree 39728-S, which sets technical standards covering sterile processing, qualified staff, appropriate equipment and general safety infrastructure.
So the operative questions for a patient are answerable: is this facility licensed, is this specific therapy authorised, and what evidence was submitted in support of it.
Why regulatory difference is not evidence of efficacy
The most important thing we can tell a reader considering this. Regulatory frameworks differ across countries for reasons that often have little to do with the underlying evidence — different classification of whether something is a drug, biologic, device or procedure; different latitude for physician discretion on off-label use; different resourcing; different institutional temperament.
A treatment being available in Costa Rica and not at home may mean the evidence is adequate and the classification differs. It may also mean nobody has funded an approval application. It may mean the evidence is thin. Availability is not information about whether something works, in either direction.
Some of what is marketed under the regenerative banner is well supported. A considerable amount is not, and it is sold at high prices to people who badly want it to work. That combination warrants more scrutiny abroad, not less.
A framework for vetting a clinic
- Is the facility licensed? Ask for the habilitación and verify it.
- What evidence supports this therapy for my indication? Not the category — the specific use. Ask for citations and read them, or have someone read them.
- Who administers it? Named physician, credentials, where they trained, licensed to practise in Costa Rica, present during treatment.
- What is the full protocol? What is administered, at what dose, over how many sessions, with what follow-up included.
- What happens if there is an adverse event? Which hospital, what transfer arrangement, who bears the cost.
- What would count as this not working? A provider unable to describe failure is not describing medicine.
A warning sign worth naming: pricing that varies with what the patient appears able to pay rather than with what is administered.
Keep your own physician involved
People who navigate this well treat treatment abroad as an addition to their existing medical relationship rather than a replacement. Tell your regular physician what you are considering even if you expect scepticism, and bring records back so anything administered is on file. Parallel, unconnected medical lives are how interactions get missed and adverse events get misattributed.
Minimal versus more than minimal manipulation
The distinction the decree draws is worth understanding, because it determines the authorisation route and tells you something about what you are being offered.
Minimally manipulated autologous therapy — the patient own cells, subject to limited processing — follows the route requiring a request to the health authority with scientifically reasoned justification that the procedure has a reasonable prospect of success, supported by preclinical or clinical evidence of efficacy and safety.
More than minimally manipulated cells — expanded, differentiated or substantially processed — sit in a different category with its own authorisation pathway, reflecting the greater regulatory concern that comes with greater processing.
A practical consequence for patients: ask which category the specific therapy falls into and what authorisation the clinic holds for it. A provider who cannot answer that clearly is either not operating within the framework or does not understand it, and neither is reassuring.
Reading evidence claims critically
Clinics vary enormously in how they present evidence, and a few patterns are worth recognising.
Category evidence substituted for indication evidence. Studies showing that a cell type has effects in some condition are frequently offered as support for using it in an unrelated condition. Ask specifically what evidence exists for your indication.
Mechanism presented as outcome. A plausible biological rationale is not evidence that a treatment improves patient outcomes. Many interventions with excellent mechanistic stories fail in trials.
Testimonials in place of data. Patient stories are compelling and uninformative — they cannot distinguish treatment effect from natural history, regression to the mean or placebo.
Registered trials cited as completed evidence. A trial registration is a plan, not a result. Check whether it published.
None of this means these therapies do not work. It means the burden of assessment shifts to you when the regulator is doing less filtering, and these are the questions that assessment requires.
The financial dimension
Worth naming plainly. Elective regenerative interventions are self-funded, frequently expensive, and marketed to people experiencing conditions that conventional medicine has not resolved — a population that is, by definition, motivated and vulnerable.
Two practical safeguards. Establish the total cost of the full protocol in writing before starting, including follow-up sessions, because staged pricing that escalates once treatment has begun is a recognised pattern. And be sceptical of pricing that appears calibrated to what the patient can pay rather than to what is administered.
Set a decision rule before you travel about what you will and will not agree to on site. Decisions made in a clinic after a persuasive consultation are harder to make well.
Frequently asked
Do I need residency to access treatment?
No. Costa Rican private clinics and hospitals treat international patients directly. Residency changes the economics of ongoing care but is not a prerequisite.
What about peptides specifically?
Peptide classification and availability vary by substance and are handled under general pharmaceutical and medical practice regulation rather than the stem cell decree. This is substance-specific and we would not generalise — ask the treating physician what the regulatory basis is for anything proposed.
Can I take treatments home?
Importing substances into your home country is a separate legal question from receiving treatment abroad, with real consequences. Do not assume lawful administration here implies lawful importation there.
Will insurance cover it?
Generally not. Elective regenerative interventions are typically self-funded regardless of jurisdiction and should be budgeted as such.
Is autologous treatment safer than donor cells?
Using a patient own cells avoids certain immune considerations and sits in a different regulatory category, but it is not automatically safe — processing, handling and administration all carry risk. Ask about the specific procedure rather than relying on the autologous label.
How do I verify a clinic licence?
Facilities require a health facility licence (habilitación) under Decreto 39728-S. Ask to see it and verify with the Ministry of Health rather than accepting a claim.
Should I tell my doctor at home?
Yes, even if you expect scepticism. Undisclosed treatment is how interactions are missed and adverse events misattributed. Bring records back so anything administered is on your file.
Talk it through with someone who has done it
MOFU decisions like these turn on details that vary by property, by family and by the month you file. Our team at Golden Visa Costa Rica works alongside Costa Rican counsel every week on exactly these questions, and we will tell you plainly where your situation is straightforward and where it is not. Book a private consultation to get specifics for your circumstances.
This article is general information, not legal, immigration, tax or investment advice. Costa Rican rules change and are applied to individual facts; figures cited were accurate at the time of writing and should be confirmed. Engage a qualified Costa Rican attorney and your own tax adviser before acting.